Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00515021 · ClinicalTrials.gov registry record · Phase 4
Diurnal Variation of Plasminogen Activator Inhibitor-1
A Phase 4 study of Metabolic Syndrome X, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT00515021: Completed Phase 4 study of Metabolic Syndrome X, sponsored by Vanderbilt University Medical Center.
NCT00515021 is a Phase 4 study of Metabolic Syndrome X that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 21 participants, below the 71-participant average among 10 other Metabolic Syndrome X trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00515021, a Phase 4 study of Metabolic Syndrome X, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine if nighttime administration of an aldosterone antagonist would effectively lower peak plasma Plasminogen Activator Inhibitor-1 (PAI-1) levels more effectively than morning administration.
Primary Outcome
baseline PAI-1 levels prior to drug administration
Conditions Studied
Interventions
- DRUG Eplerenone (Morning)
- DRUG Eplerenone (Night-time)
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2007-04 |
| Est. Completion | 2010-04 |
| Phase | Phase 4 |
What the finished NCT00515021 record still lists
NCT00515021 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 71-participant average among 10 other Metabolic Syndrome X trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Metabolic Syndrome X appearing as the primary indexed condition, and to 2 interventions - of which Eplerenone (Morning) is the first listed.
NCT00515021 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT00515021 about?
NCT00515021 is a clinical study titled "Diurnal Variation of Plasminogen Activator Inhibitor-1". To determine if nighttime administration of an aldosterone antagonist would effectively lower peak plasma Plasminogen Activator Inhibitor-1 (PAI-1) levels more effectively than morning administration.
What is the current status of trial NCT00515021?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2007-04. Estimated completion is 2010-04.
What conditions does trial NCT00515021 study?
This clinical trial studies the following conditions: Metabolic Syndrome X.
What interventions are being tested in trial NCT00515021?
The interventions under investigation include: Eplerenone (Morning) (DRUG), Eplerenone (Night-time) (DRUG).
Who is sponsoring clinical trial NCT00515021?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00515021 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metabolic Syndrome X
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00515021's enrollment target sits among peer trials
21 10th of 10 higher than 1 of 10 other Metabolic Syndrome X trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metabolic Syndrome X trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia
COMPLETED · Phase 4
-
Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes
COMPLETED · Phase 4
-
Oral Contraceptives in the Metabolic Syndrome
COMPLETED · Phase 4
-
Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome
COMPLETED · Phase 4
-
Effects of Resistance and Aerobic Exercise on Cardiovascular Health
COMPLETED · Phase 2
-
Effect of Dietary Amino Acid Profile on Lipoprotein Metabolism, Vascular Reactivity and Inflammatory Markers
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia